In case you missed: RFK Jr. fires entire CDC vaccine advisory panel The Beyfortus shot was recommended by ACIP in 2023 for babies under 9 months old who are entering their first RSV season.

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Active immunization of individuals 18 years of age and older for the prevention of ...

The Food and Drug Administration on Wednesday approved the world’s first RSV vaccine: a shot for adults ages 60 and up, made by pharmaceutical giant GSK.

Find earnings, economic, stock splits and IPO calendars to track upcoming financial events from Yahoo Finance.

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

"FDA approves Pfizer's Abrysvo, the first RSV vaccine for high-risk adults aged 18-59. Based on Phase 3 trial data, it offers broad coverage and is also approve ...

The European Commission on Friday approved Moderna's respiratory syncytial virus (RSV) vaccine for older adults -- the first time the bloc has authorised an mRNA shot against a disease other than ...

Moderna's mRNA vaccine mRESVIA has been recommended for a marketing authorization in the EU to protect against respiratory syncytial virus in older adults.

The Food and Drug Administration (FDA) recently approved an expansion of a respiratory syncytial virus (RSV) vaccine for use in at-risk adults over the age of 50.

Moderna’s mResvia is now the third FDA-approved RSV vaccine and the first one based on mRNA technology. It will compete for market share against RSV shots from GSK and Pfizer that won their FDA ...

The FDA approved the first-ever mRNA-1345 vaccine (mRESVIA) for respiratory syncytial virus (RSV) for people ages 60 and older to protect against lower respiratory tract disease, Moderna announced ...